Global Antibiotic R&D Partnership (GARDP)’s Post

Thanks for the Fleming Initiative and Lord Darzi for highlighting this important #patientsafety issue for all of us. We did to use all of our tools of diagnostics, education and #clinicaldecisionmaking to ensure we can treat infections in the future. #healthcare #antibioticstewardship #AMR. #medicalinnovation

Yesterday’s High-Level meeting on Antimicrobial Resistance has underlined the need for global cooperation and urgent action if we are to truly tackle its looming threat. As our executive chair Lord Ara Darzi wrote in The Economist ahead of joining leaders at UNGA, by 2030 no antibiotic should be prescribed without a proper diagnosis that identifies the underlying cause as bacterial infection. This change will “require unprecedented co-operation, significant investment in diagnostic technologies and a fundamental shift in prescribing practices worldwide, including affordable diagnostics and support from wealthier nations for lower income countries" The Fleming Initiative will continue to foster collaboration across scientific, technology, clinical, policy and public engagement experts to ensure that we are able to drive the change needed to keep antibiotics for generations to come. Read more in this Op-Ed ⤵️ https://lnkd.in/eMNCkt8S

A lot of good is being done in trying to stop this silent pandemic, but I still maintain that more needs to be done concerning informing the general public, giving them the knowledge and power to be part of the solution. Consumption of antibiotics increased to 16,5% from 2016 to 2023. "Without reductions in rapidly developing nations, by 2030, it is projected that global antibiotic consumption will increase by 52.3 percent from an estimated 49.3 billion in 2023 to 75.1 billion DDDs."

Check out the latest coverage of the OHT collaborative study in PNAS on global antibiotic consumption in Infectious Disease Advisor. "The researchers found that from 2016 to 2023, estimated antibiotic consumption in reported countries increased 16.3 percent, from 29.5 to 34.3 billion defined daily doses (DDDs), reflecting a 10.6 percent increase in the consumption rate from 13.7 to 15.2 DDDs per 1,000 inhabitants per day. Upper- and lower-middle income countries had the most pronounced increases." Read it here: https://lnkd.in/d4ih4nBX

McMaster researchers have discovered a way to make deadly drug-resistant bacteria vulnerable to a commonly used antibiotic. Their findings: 🔬Offer a way to fight dangerous infections without needing new drugs 💊Open the door to new utility for old drugs 🌍Provide deeper understanding in the fight against antimicrobial resistance — a top global health concern Learn more: https://ow.ly/Itzq50UBVSz ____ McMaster Faculty of Health Sciences Michael G. DeGroote Institute for Infectious Disease Research

Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 -- new paper out in The Lancet. "In 2021, we estimated 4·71 million (95% UI 4·23–5·19) deaths were associated with bacterial AMR, including 1·14 million (1·00–1·28) deaths attributable to bacterial AMR. " "Our forecasts show that an estimated 1·91 million (1·56–2·26) deaths attributable to AMR and 8·22 million (6·85–9·65) deaths associated with AMR could occur globally in 2050." https://lnkd.in/g3PfTCAD

Antimicrobial resistance poses a serious threat to public health worldwide. We discuss the advantages and challenges of expanding the usage of phages as an alternative or adjunctive treatment for antimicrobial-resistant bacterial infections. The ability of some phages to revert the resistance against antibiotics appears to be a great advantage of phage therapy despite the inevitable emergence of phage-resistant strains.

Unlocking the Power of Antibiotics: What Everyone Should Know Did you know that antibiotics💊 have been saving lives for nearly a century since their discovery in 1928? These powerful medicines are designed to fight infections caused by bacteria. For example, penicillin💊 allowed doctors to effectively treat life-threatening infections like pneumonia and tuberculosis. But how exactly do antibiotics work? They either kill bacteria (bactericidal) 🧫or inhibit their growth (bacteriostatic). Penicillin,💊 for instance, works by interfering with a bacterium's ability to build its protective cell wall, ultimately killing the bacteria. Other antibiotics, like macrolides (e.g., erythromycin), 🧫stop bacteria from producing essential proteins they need to grow and multiply. However, antibiotics don’t work against viruses, so using them for a cold🤧 or flu is not only ineffective but also harmful in the long run. This misuse of antibiotics💊 contributes to a critical problem called antibiotic resistance. As bacteria adapt to survive, they become resistant to the drugs meant to kill them, making infections harder to treat. Subsequently, we’ll explore how resistance develops and what it means for the future of medicine. Understanding antibiotics💊🧫 is the first step toward fully benefiting from their ability to treat infections. Use them wisely. #Antibiotics #Healthcare #BacterialInfections #AntibioticResistance #PublicHealth #ScienceExplained

The DANGER and IMPACT of the global problem of Antimicrobial Resistance (AMR) has just been re-quantified in an excellent publication in the The Lancet: "Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050". AMR has become - and will worsen - into a catastrophic "silent pandemic". 𝙈𝙖𝙞𝙣 𝙛𝙞𝙣𝙙𝙞𝙣𝙜𝙨 𝙧𝙚𝙡𝙖𝙩𝙚𝙙 𝙩𝙤 𝘼𝙈𝙍 𝙛𝙧𝙤𝙢 1990-2021: - While AMR deaths decreased in children under 5 years old, 𝘼𝙈𝙍 𝙙𝙚𝙖𝙩𝙝𝙨 𝙞𝙣𝙘𝙧𝙚𝙖𝙨𝙚𝙙 >80% 𝙛𝙤𝙧 𝙖𝙙𝙪𝙡𝙩𝙨 >70 𝙮𝙚𝙖𝙧𝙨 𝙤𝙡𝙙. - For Gram-negative bacteria, 𝙧𝙚𝙨𝙞𝙨𝙩𝙖𝙣𝙘𝙚 𝙩𝙤 𝙘𝙖𝙧𝙗𝙖𝙥𝙚𝙣𝙚𝙢𝙨 𝙞𝙣𝙘𝙧𝙚𝙖𝙨𝙚𝙙 𝙢𝙤𝙧𝙚 𝙩𝙝𝙖𝙣 𝙖𝙣𝙮 𝙤𝙩𝙝𝙚𝙧 𝙖𝙣𝙩𝙞𝙗𝙞𝙤𝙩𝙞𝙘 𝙘𝙡𝙖𝙨𝙨, rising from 619K to 1 Million “associated” deaths and from 127K to 216K directly “attributable” deaths - Regions with the highest AMR mortality rate in 2050 are forecasted to be 𝙨𝙤𝙪𝙩𝙝 𝘼𝙨𝙞𝙖 𝙖𝙣𝙙 𝙇𝙖𝙩𝙞𝙣 𝘼𝙢𝙚𝙧𝙞𝙘𝙖 𝙖𝙣𝙙 𝙩𝙝𝙚 𝘾𝙖𝙧𝙞𝙗𝙗𝙚𝙖𝙣 - Increases in deaths attributable to AMR in 2050 will be 𝙡𝙖𝙧𝙜𝙚𝙨𝙩 𝙖𝙢𝙤𝙣𝙜 𝙩𝙝𝙤𝙨𝙚 >70 𝙮𝙚𝙖𝙧𝙨 𝙤𝙡𝙙 - A cumulative 11.1 million AMR deaths could be averted through the development of a Gram-negative drug pipeline addressing AMR pathogens https://lnkd.in/edWBWtRW

Top Hits #CountDown #6 Experimental antibiotic treatment for Lyme heads for human safety trials. Human safety trials of a novel antibiotic treatment for Lyme disease developed by Northeastern professor Kim Lewis began in April. According to Dr. Lewis, hygromycin-A targets spirochetes like Lyme disease without harming anything else in the gut microbiome. READ MORE: https://lnkd.in/e8ZpZbE7 #topstories #LymeDisease